College Stock: Penny Stock News

These five penny stocks have made The Dean’s List of price gainers for Monday, August 30, 2010:

HTCH $3.46 +21.40%
Hutchinson Technology Incorporated (NASDAQ: HTCH) together with its subsidiaries, designs, develops, manufactures, and supplies suspension assemblies for disk drives in Thailand, Hong Kong, Japan, the United States, China, and internationally. Despite the Company not issuing significant material news, HTCH traded 2,535,635 shares, or more than ten times its 10-day average volume. Trading for a high of $3.88 on the day, HTCH shares gained as much as 36%.

NED $2.21 +19.45%
Noah Education Holdings, Ltd. (NYSE: NED) and its subsidiaries provide interactive electronic educational materials to the Chinese elementary, middle, and high school students. Last Wednesday, in the Company’s latest announcement, NED announced the resignation of two of its board of directors due to personal reasons. Trading as high as $2.27 per share, NED gained as much as 22.7% on volume far exceeding both its 10 and 90-day averages.

ZIXI $2.76 +12.65%
Zix Corporation (NASDAQ: ZIXI) provides Internet-based applications in a Software-as-a-Service model to connect, protect, and deliver information, enabling the use of the Internet for applications requiring security in the healthcare, finance, insurance, and government sectors primarily in the United States. Today, ZIXI also appeared to be a mystery mover penny stock, trading more than six times its 3 month average volume, moving to a high of $2.76, where it closed for the day.

SMTX $2.90 +11.11%
SMTC Corporation (NASDAQ: SMTX) provides advanced electronics manufacturing services to original equipment manufacturers worldwide. Although the Company hasn’t issued news since it updated financials for the quarter ended July 4, 2010 earlier this month, SMTX shares gained more than 11%, trading more than 1.5 times its 3 month average volume.

PSTI $1.11 +9.90%
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a development stage bio-therapeutics company that engages in the research, development, and production of placental-derived adherent stromal cells. This morning, the Company announced its PLX cell therapy product, derived from human placenta, “a non-controversial, non-embryonic, adult stem cell source,” was selected as the only cell therapy product candidate to enter into a study seeking treatments for diastolic heart failure in the European Commission’s Seventh Framework Program (FP7). Today, PSTI shares gained nearly 18%, trading 468,436 shares, or more than seven times its 10-day average volume.